Houston, Texas (PRWEB) June 13, 2014
Endothelix is pleased to announce that Cenegenics® New York is now offering the VENDYS® test. VENDYS is the only FDA-cleared, fully-automated, operator-independent, office-based endothelial function (vascular reactivity) measurement device in the market. VENDYS testing allows for the early detection and treatment of cardiovascular disease, the number one cause of mortality in the United States. Over 30% of the time, the first symptom of cardiovascular disease is an actual heart attack or stroke, earning the name "the silent killer." The good news is cardiovascular disease is preventable with proper screening, testing and active prevention.
By incorporating the VENDYS test into its Heart Disease & Stroke Prevention program, the Cenegenics NY center is continuing its proud tradition of going above and beyond in enabling optimal cardiovascular health for its patients. Dr. Joseph E. Bosiljevac, Jr., Dr. Keith Fleischman, and Dr. George Shapiro lead its medical team. Dr. Keith Fleischman states, “At Cenegenics New York we are extremely interested in understanding our patient's cardiovascular health and want to construct our treatment protocols with their total health picture in mind. It is important to understand everything we can about our patients in order to assess and address their unique needs. From a cardiovascular standpoint, we need to understand the functional health of their blood vessels, not simply rely on structural analysis and lipid panels. Assessment of endothelial dysfunction is one of the earliest signs of cardiovascular risk, seen as early as people in their 30s. VENDYS gives us insight into endothelial function in patients and is a useful tool in measuring response to therapy.” The Cenegenics New York center is located on the 55th Floor of the Trump Building at 40 Wall Street, New York City, NY 10005.
The VENDYS automated technology is designed to help physicians detect vascular dysfunction and measure the fitness of a patient’s cardiovascular system. It is an office-based test and provides a patient-friendly report in 15 minutes by simply measuring the temperature in one’s fingers.
The VENDYS test begins with an automated blood pressure measurement, followed by a tightening of the cuff on the right arm. During the cuff occlusion period, fingertip temperature in the right hand falls due to the absence of warm circulating blood. Once the cuff is released, blood flow rushes into the forearm and hand, causing a temperature rebound in the fingertip, which is directly proportional to the vascular function. The higher the temperature rebound, the better the vascular function.
For more information, go to http://www.endothelix.com.
Endothelix, Inc. is a cardiovascular device company based in Houston, Texas and is focused on non-invasive vascular function measurement. The company originated from the Texas Medical Center-Houston from a collaborative project between the Texas Heart Institute and The University of Texas Health Science Center at Houston. Endothelix received a $1 million award from the Texas Emerging Technology Fund to develop the VENDYS® technology.
Endothelix’s first product is VENDYS, a non-invasive, inexpensive, and easy to use vascular function test. VENDYS is FDA cleared and is currently marketed throughout the United States, Europe and Canada. The company has a pipeline of innovative products. More info: http://www.endothelix.com
Founded in 1997 by Alan Mintz, MD and John Adams, Cenegenics has established an important presence in the international medical community, bridging the gap between conventional medicine and a scientifically based, proactive intervention. Cenegenics is the world’s largest Age Management medical practice, having treated over 25,000 patients — 10% of whom are physicians or their families — over the last 17 years. More info: http://www.cenegenics-nyc.com